Literature DB >> 31813884

Antioxidant, cytotoxic and hyperalgesia-suppressing activity of a native Shilajit obtained from Bahr Aseman mountains.

Mandana Jafari1, Hamid Forootanfar2, Alieh Ameri3, Amir Foroutanfar4, Mahbobe Adeli-Sardou5, Hamid Reza Rahimi6, Amir Najafi7, Nasser Zangiabadi8, Mojtaba Shakibaie2.   

Abstract

Shilajit, a blackish-brown exudation obtained from steep rocks of different mountains, has been longly used as a therapeutic agent in traditional medicine. The present study was designed to evaluate the antioxidant, cytotoxic and hyperalgesia-suppressing activity of the aqueous and DMSO extracts of a native Shilajit. The antioxidant and cytotoxic effects of Shilajit extracts was determined using DPPH scavenging activity and MTT assay methods, respectively. In order to examine the hyperalgesia-suppressing activity of the Shilajit aqueous extract the STZ-induced diabetic animals were subjected to oral administration of the extract (50, 100 and 200 mg/kg daily) for six weeks followed by evaluating the behavioral examination (hot plate and tail flick tests) compared to those of diabetic control (Sham) and vehicle groups. The obtained results of antioxidant evaluation of Shilajit represented scavenging activity of 50% at concentration of 2500 μg/mL and 6000 μg/mL in the case of aqueous and DMSO extracts, respectively. Cytotoxic study of water extract of Shilajit revealed IC50 of 727.5±1.9 μg/mL and 1103±3.2 μg/mL on cell lines of MCF-7 (breast cancer) and A549 (lung cancer), respectively. Thermal pain response examination of diabetic rats treated with aqueous extract of Shilajit (100 mg/kg and 200 mg/kg) for six weeks reduced hyperalgesia compared to vehicle and Sham groups. To sum up, considering the moderate antioxidant and hyperalgesia-suppressing activity of this native Shilajit make it as a suitable candidate for further investigation after isolation and characterization of the active compounds.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31813884

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment.

Authors:  T Kloskowski; K Szeliski; K Krzeszowiak; Z Fekner; Ł Kazimierski; A Jundziłł; T Drewa; M Pokrywczyńska
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

2.  Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats.

Authors:  Ebtihaj J Jambi; Fawzia Abdulaziz Alshubaily
Journal:  Saudi J Biol Sci       Date:  2022-07-25       Impact factor: 4.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.